Silexion Therapeutics Corp (SLXN) stock forecast & analysis
0.4355
NasdaqCM · USD
Up: +0.0555, +14.6%
0.4054Down: -0.0301, -6.9%
2 analyses
- Open
- 0.3869
- Previous close
- 0.3800
- Day range
- 0.3840 – 0.4492
- 52-week range
- 0.3220 – 42.60
- Volume (shares)
- 26.83M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 5.56M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -0.36
- Market cap
- 2.42M
Market Scanner’s AI analysis of Silexion Therapeutics Corp (SLXN), updated September 2026: Silexion Therapeutics' preclinical findings and clinical trial initiation contrasted with a significant stock price decline and public offering.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Silexion Therapeutics Corp (SLXN) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Silexion Therapeutics' preclinical findings and clinical trial initiation contrasted with a significant stock price decline and public offering.
Recent analyses for Silexion Therapeutics (SLXN) covered its participation in industry conferences and the initiation of a Phase 2/3 clinical trial for SIL204, alongside positive preclinical data. This was juxtaposed with a significant stock price decline, trading well below its 50-day and 200-day moving averages, and news of a $2.5 million public offering.
SLXN news & sentiment
News reports indicated a mixed sentiment, with conference participation and preclinical data overshadowed by a securities offering that led to a pre-bell share price decline. Social media discussion was not covered in the provided notes.
SLXN technical picture
The stock price traded significantly below its 50-day and 200-day Simple Moving Averages, indicating a strong downtrend. Momentum indicators showed bearish sentiment, though some readings suggested oversold conditions with strong buying pressure, hinting at potential reversal.
Fundamentals
Silexion Therapeutics has consistently reported significant net and operating losses, with recent quarterly losses of $3.55 million. The company's market capitalization has been volatile, with recent figures around $1.89 to $2.35 million, and its stock price has traded significantly below its 50-day and 200-day moving averages.
Factors discussed — upside
- Positive preclinical findings for SIL204 in KRAS-driven cancers.
- Initiation of a Phase 2/3 clinical trial for SIL204 in pancreatic cancer.
- Money Flow Index (MFI) indicating strong buying pressure.
- Recent 7-day price change showing a notable increase.
Factors discussed — risks
- Current stock price significantly below 50-day and 200-day SMAs.
- Consistent and significant net and operating losses reported.
- Announcement of a $2.5 million public offering.
- Recent 30-day and 91-day price changes indicating a substantial downtrend.
- RSI in oversold territory, though potentially sustained by downtrend.
- Clinical trial progress
- Financial performance
- Market sentiment
- Capital raising
Summary updated .
SLXN technical indicators
Common technical indicators for SLXN, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.21 | Price below |
| 10-day exponential moving average | 0.38 | Price above |
| Relative strength index (14-day) | 35.73 | Neutral |
| MACD line (12/26/9) | -0.2120 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.32 – 0.42 | Price above the upper band |
Analyses
Recent SLXN.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Silexion Therapeutics Corp?
- The bull case centers on positive preclinical findings and the initiation of a Phase 2/3 clinical trial for SIL204, alongside strong buying pressure indicated by the Money Flow Index and a recent 7-day price increase.
- What are the risks for Silexion Therapeutics Corp?
- Risks highlighted include the stock price trading significantly below its long-term moving averages, consistent net and operating losses, and the recent announcement of a $2.5 million public offering, all contributing to a substantial downtrend.
- Is Silexion Therapeutics Corp bullish or bearish?
- Recent AI analyses of Silexion Therapeutics Corp examined factors on both sides. Discussed upside: The bull case centers on positive preclinical findings and the initiation of a Phase 2/3 clinical trial for SIL204, alongside strong buying pressure indicated by the Money Flow Index and a recent 7-day price increase. Discussed risks: Risks highlighted include the stock price trading significantly below its long-term moving averages, consistent net and operating losses, and the recent announcement of a $2.5 million public offering, all contributing to a substantial downtrend. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Silexion Therapeutics Corp?
- News reports indicated a mixed sentiment, with conference participation and preclinical data overshadowed by a securities offering that led to a pre-bell share price decline. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Silexion Therapeutics Corp?
- Every analysis of Silexion Therapeutics Corp runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh SLXN.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every SLXN.US report already in the library